Dr. Kunz on the Importance of Tailoring Treatments to Patients With NETs ByPamela L. KunzNovember 18th 2021Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.
Dr. Kunz on the Impact of Lanreotide's Approval for Neuroendocrine TumorsByPamela L. KunzJanuary 16th 2015Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.